Biotech Pulse vs Stock Earning Analysis
Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.
Biotech Pulse
Access real-time biotech industry intelligence, including FDA approvals, PDUFA dates, and SEC filings. Stay ahead of market news with instant alerts and detailed company and drug information. Ideal for investors and analysts seeking an edge in the fast-paced biotech sector.
- Real-time FDA approval and PDUFA date alerts
- EU EMA marketing authorisation feed
- SEC filings and clinical trial updates
- Forward catalyst calendar
- Push notifications for watchlisted tickers
- Insider buys and institutional holdings (Pro)
- Patent timelines and drug shortages (Pro)
Read full descriptionHide full description
The biotech catalyst tracker for serious investors. Real-time FDA approvals, PDUFA dates, EMA and CHMP committee opinions, SEC filings, clinical trial readouts, and primary-source company news — pushed the moment they hit the regulatory record. WHO IT'S FOR Biotech investors, pharma analysts, healthcare hedge funds, and retail traders who need to see what just happened on a name BEFORE the wire-service summary hits Twitter. FREE FEATURES (no account, no signup) • Real-time FDA approval, PDUFA, CRL, and Warning Letter alerts • EU EMA marketing authorisation feed (UK + EEA centralised approvals) • SEC 8-K filings, press releases, and clinical trial updates • Forward catalyst calendar with PDUFA, AdCom, and CHMP dates • Push notifications when a watchlisted ticker has an event • Watchlist + per-ticker News, Pipeline, Drugs, Intelligence tabs • Indication / drug-class search ("multiple sclerosis", "GLP-1", "CAR-T") • Drug detail with FAERS adverse-event severity and primary-source link to Drugs@FDA • Watchlist Compare view — side-by-side pipeline depth + next catalyst BIOTECH PULSE PRO ($9.99/mo or $79.99/yr, with 7-day free trial) Twelve institutional-grade Pro features, every one sourced from a primary regulatory or scientific feed: • Insider buys — SEC Form 4 executive open-market purchases, 10b5-1 plans filtered out • 13F institutional holdings — quarterly changes, biotech-whale callouts (Baker Bros, BVF, RA Capital, Perceptive) • 8-K dilution radar — automatic offering / shelf / ATM classification • 8-K Item 8.01 content classifier — CRL, PDUFA, AdCom, trial readout, partnership, regulatory filing categories • Material agreements — 8-K Item 1.01 partnership / licensing / supply detection • AdCom calendar — Federal Register FDA Advisory Committee meetings + briefing-doc URLs • Orange Book + USPTO patent timelines — every unexpired patent with USPTO Patent Term Adjustment chips (PTA extends patent expiry past the Orange Book listing — the most under-priced biotech signal), Re-exam warning flags, family-size hints, and one-tap to the patent document on Google Patents • FDA Warning Letter history • FDA device clearances — 510(k) and PMA by manufacturer • DailyMed label history — every SPL version bump (indication, black-box, REMS) • CMS Open Payments — KOL payment network per sponsor • CMS Part D utilization — 5 years of Medicare prescription volume • Drug shortages — FDA-tracked active shortages with push alerts on status changes • Conference abstracts — ASH, ASCO, AHA, AAN, DDW • Custom alert rules — unlimited, all 4 trigger types including 8-K Item filtering 100% PRIMARY-SOURCE DATA SEC EDGAR. openFDA. EMA. CHMP. Health Canada. CMS. NIH. Federal Register. ClinicalTrials.gov. DailyMed. USPTO. ash.confex.com. No Bloomberg, no Refinitiv, no FactSet, no paid data vendors. No AI hallucinations. No analyst recommendations. Just the data. NO TRACKING No analytics SDK. No advertising SDK. No cross-app tracking. No account required. External article links open in Safari's isolated process. We don't know who you are. Pro auto-renews unless cancelled at least 24 hours before the end of the current period. Cancel anytime in iOS Settings → Apple ID → Subscriptions. Terms of Use: https://bioturd.com/terms Privacy Policy: https://bioturd.com/privacy
Stock Earning Analysis
Access live financial data for public companies, including S-1 filings, earnings reports, and sector analysis. Track company performance with AI-powered insights and investor scoring frameworks. All data is sourced directly from SEC EDGAR.
- Live S-1 filing feed
- Missed earnings tracker
- Sector analysis with key metrics
- Deep dive company financial performance
- AI-powered earnings analysis
- Investor scoring frameworks
- SEC S-8 filing data
Read full descriptionHide full description
Dashboard Open the app to a live overview of your saved S-1 filings and tracked companies — everything that matters, front and center. S-1 Filing Feed Browse and search every S-1 and S-1/A IPO filing on SEC EDGAR in real time. Filter by date range, bookmark filings to your watchlist, and tap through to the full document on SEC.gov. Missed Earnings See which companies fell short of Wall Street expectations over the last 30 days. Filter by ticker or name, and add underperformers directly to your companies list for deeper tracking. Sector Analysis Explore market sectors — Technology, Healthcare, Financials, Energy, and more — with live market cap, P/E ratio, revenue growth, and net margin for the leading companies in each space. Company Earnings Intelligence Add any public company and get a deep dive into their financial performance: • Quarterly revenue, net income, EPS, and gross margin with year-over-year comparisons • Interactive 1M–5Y stock price chart • AI-powered earnings analysis using Apple Intelligence (iPhone 15 Pro and later) • Analyst ratings with consensus, price targets, and upside/downside from current price • Three investor scoring frameworks — Buffett & Munger (quality value), Chris Hohn (quality compounder), and a16z (tech growth) — grading each company from A to F • SEC S-8 equity compensation filings showing employee stock plan registrations Data You Can Trust All financial data is sourced directly from SEC EDGAR (the official U.S. securities regulator) and public market data providers — no subscriptions, no paywalls.
Screenshots
Verdict
The clearest difference is price: Biotech Pulse at Free against Stock Earning Analysis's $2.99. Biotech Pulse also leads on iOS requirement (15.1 vs 26.5). Stock Earning Analysis's advantage is in-app purchases (none vs 2). On rating, ratings volume, update cadence and ads there is nothing between them.
Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS
Biotech Pulse is free to download; Stock Earning Analysis costs $2.99 up front. Biotech Pulse sells 2 in-app purchases, starting at $14.99 per month. Stock Earning Analysis asks for nothing beyond the download.
On the App Store both sit at effectively the same score — 5.0 for Biotech Pulse against 5.0 for Stock Earning Analysis. Both are backed by a comparable volume of ratings — 5 and 2 respectively.
Biotech Pulse ships an update weekly, Stock Earning Analysis fortnightly. The most recent releases landed on November 15, 2026 and November 13, 2026 respectively.
| Parameter | Biotech Pulse | Stock Earning Analysis |
|---|---|---|
| Price | Free — better | $2.99 |
| Rating | 5.0 (5 ratings) | 5.0 (2 ratings) |
| Number of ratings | 5 — better | 2 |
| Update frequency | Weekly — better | Fortnightly |
| Ads | No | No |
| In-app purchases | Yes | No — better |
| Monetization | Freemium — better | Paid |
| Devices | iPhone, iPod | iPhone, iPad |
| Requires iOS | 15.1 — better | 26.5 |
| Further details — not scored | ||
| Size | 37 MB | 3 MB |
| Age rating | 4+ | 4+ |
| Developer | MEAS Partners, LLC | CHARLES KELLY BISSELL |
In-app purchases
Biotech Pulse
- Biotech Pulse Pro$14.991 Month
- Biotech Pulse Pro7 Days trial$119.001 Year
Stock Earning Analysis
No in-app purchases
Questions
Is Biotech Pulse free?
Is Stock Earning Analysis free?
Which has better reviews, Biotech Pulse or Stock Earning Analysis?
Do Biotech Pulse or Stock Earning Analysis have ads?
Which is updated more often, Biotech Pulse or Stock Earning Analysis?
Other comparisons















